

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

RESIGNATION OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY, APPOINTMENT OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces the following changes with effect from 18 April 2019:

1. the resignation of Mr. Leung Wai Fung, Joseph as the chief financial officer and company secretary of the Company, and ceased to act as the authorised representative of the Company.
2. the appointment of Mr. Li Zhen as the chief financial officer of the Company; and
3. the appointment of Mr. Pang Wai Ching as the company secretary and the Authorised Representative under the Listing Rules.

RESIGNATION OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Leung Wai Fung, Joseph (“**Mr. Leung**”) has tendered his resignation as the chief financial officer and company secretary of the Company, and ceased to act as an authorised representative of the Company (the “**Authorised Representative under the Listing Rules**”) as required under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 18 April 2019.

Mr. Leung has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE

Following the resignation of Mr. Leung, the Board is hereby pleased to announce that, with effect from 18 April 2019, Mr. Li Zhen (“**Mr. Li**”) has been appointed as the chief financial officer and Mr. Pang Wai Ching (“**Mr. Pang**”) has been appointed as the company secretary of the Company and the Authorised Representative under the Listing Rules.

Mr. Li, aged 41, is a member of the Chinese Institute of Certified Public Accountants and Association of Chartered Certified Accountants. Mr. Li obtained a Bachelor of Management in Accountancy from Central University of Finance and Economics (中央財經大學).

Mr. Li has over 18 years of experience in accounting, auditing and finance. He started his career at KPMG Huazhen from September 2000 to April 2010, with his last position as a senior manager. He worked as the financial controller at Beijing BOE Vision-Electronic Technology Company Limited (北京京東方視迅科技有限公司) from May 2010 to April 2012. He worked as the chief financial officer at Shenzhen Aishide Company Limited (深圳市愛施德股份有限公司) from August 2012 to December 2014. He also served as the chief financial officer at Evercare (Beijing) Holding Group Company Limited (伊美爾(北京)控股集團股份公司) from May 2016 to July 2017. Prior to joining our Group, he served as an assistant financial controller at Dr. Peng Telecom & Media Company Limited (鵬博士電信傳媒集團股份有限公司) from July 2017 to April 2018.

Mr. Pang, aged 30, is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Pang obtained a Bachelor of Business Administration in Accountancy from City University of Hong Kong.

Mr. Pang has over 8 years of experience in accounting, auditing and company secretarial matters. He joined KPMG in October 2010 and left the firm in November 2014 as an assistant manager. He served as an assistant manager of group internal audit department of Melco Services Limited between November 2014 and September 2015. Mr. Pang rejoined KPMG in October 2015 and left the firm in July 2017 with his last position as a manager. He also worked as the financial controller of Golden Bright Hong Kong Group Limited (金輝香港集團有限公司) from July 2017 to April 2018. He is currently a director of Techson Management Limited (德承管理有限公司).

The Board would like to take this opportunity to express its gratitude to Mr. Leung and for his valuable contribution to the Group during his tenure of service and welcome Mr. Li and Mr. Pang for their new appointments.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Changcheng
Chairman and Executive Director

Hong Kong, 18 April 2019

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Dudu as executive Directors, Mr. Wang Jianhang as non-executive Director, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Mr. Ho Ka Chun as independent non-executive Directors.